Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;31(5):917-925.
doi: 10.1007/s12282-024-01605-2. Epub 2024 Jun 15.

Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer

Yaping Huang #  1 , Chengjie Ke #  2   3 , Jiaqin Cai  1 , Xiaoxia Wei  1 , Maohua Chen  4 , Hong Sun  5
Affiliations

Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer

Yaping Huang et al. Breast Cancer. 2024 Sep.

Abstract

Background: Tamoxifen (TAM) is recommended as the first-line strategy for men with estrogen receptor (ER)-positive early breast cancer who are candidates for adjuvant endocrine therapy in ASCO guideline. Our study aims to analyze the cost-effectiveness of receiving adjuvant endocrine therapy with TAM compared to no TAM, and to assess the cost-effectiveness of using TAM with high adherence over low adherence for ER-positive early male breast cancer in the USA.

Methods: Two Markov models comprising three mutually exclusive health states were constructed: (1) the first Markov model compared the cost-effectiveness of adding TAM with not using TAM (TAM versus Not-TAM); (2) the second model compared the cost-effectiveness of receiving TAM with high adherence and low adherence (High-adherence-TAM versus Low-adherence-TAM). The simulation time horizon for both models was the lifetime of patients. The efficacy and safety data of two models were elicited from the real-world studies. Model inputs were derived from the US website and published literature. The main outcomes of two models both included the total cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs).

Results: In the first model, TAM yielded an ICER of $5707.29 per QALY compared to Not-TAM, which was substantially below the WTP threshold of $50,000.00 per QALY in the USA. Probabilistic sensitivity analysis results demonstrated a 100.00% probability of cost-effectiveness for this strategy. In the second model, High-adherence-TAM was dominated absolutely compared to Low-adherence-TAM. The High-adherence-TAM was cost-effective with a 99.70% probability over Low-adherence-TAM when WTP was set as $50,000.00/QALY. All of these parameters within their plausible ranges did not reversely change the results of our models.

Conclusions: Our study will offer valuable guidance for physicians or patients when making treatment decisions and provide an effective reference for decision-making to consider the appropriate allocation of funds to this special group.

Keywords: Adjuvant endocrine treatment; Cost-effectiveness; Male breast cancer; Tamoxifen.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Arch. 2022;480(1):85–93. - PubMed - DOI
    1. Reddington R, Galer M, Hagedorn A, et al. Incidence of male breast cancer in Scotland over a twenty-five-year period (1992–2017). Eur J Surg Oncol. 2020;46(8):1546–50. - PubMed - DOI
    1. Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009;115(2):429–30. - PubMed - DOI
    1. Sasco AJ, Lowenfels AB, Pasker-de JP. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53(4):538–49. - PubMed - DOI
    1. Key Statistics for Breast Cancer in Men. 2024. https://www.cancer.org/cancer/types/breast-cancer-in-men/about/key-stati... . Accessed 6 Mar 2024.

LinkOut - more resources